Cingulate Inc. (CING) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Cingulate Inc. is a pre-revenue biopharmaceutical company developing once-daily tablet formulations for ADHD and anxiety using its Precision Timed Release (PTR) platform. The primary product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for ADHD, and CTx-2103 (buspirone) for anxiety. This report covers the quarterly period ended March 31, 2025. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,802,691) | $(2,972,477) |
| Operating Loss | $(3,706,035) | $(2,948,217) |
| Net Loss Per Share (Basic/Diluted) | $(1.04) | $(7.21) |
| Cash and Cash Equivalents (End of Period) | $9,518,966 | $1,113,830 |
| Net Cash Used in Operating Activities | $(4,608,282) | $(8,746,360) |
| Total Debt (Current + Long-Term) | $5,048,633 | $4,963,987 |
| Accumulated Deficit | $(112,291,871) | $(95,915,920) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 25.7% to $3.7 million. Research and Development (R&D) expenses increased 23.0% to $2.2 million, driven by a reinstatement of employee base salaries in September 2024 and higher regulatory costs for the upcoming NDA submission. General and Administrative (G&A) expenses increased 30.0% to $1.5 million, primarily due to higher legal/professional fees and personnel costs.
- Debt Financing: In December 2024, the company issued a $5.48 million unsecured promissory note to Streeterville Capital, LLC. This resulted in significant interest expense ($209,671) in Q1 2025 compared to negligible interest in Q1 2024.
- Cash Position: Cash balances increased significantly from $1.1 million in Q1 2024 to $9.5 million in Q1 2025, supported by equity issuances under the At-The-Market (ATM) agreement and the Lincoln Park Purchase Agreement.
- Share Count: Weighted average shares outstanding increased from 412,126 in Q1 2024 to 3,646,893 in Q1 2025, reflecting equity raises and reverse stock splits completed in 2023 and 2024.
Guidance, Outlook, and Risks
- Product Pipeline: The company targets a mid-2025 New Drug Application (NDA) submission for CTx-1301. A Pre-NDA meeting with the FDA was held on April 2, 2025. CTx-2103 development is supported by a new $3 million grant from a private family foundation (first payment expected May 2025).
- Liquidity Outlook: Management believes current cash resources ($9.5 million) will satisfy capital needs into the fourth quarter of 2025. However, the filing explicitly states there is "substantial doubt" about the company's ability to continue as a going concern within one year without additional funding.
- Capital Strategy: The company continues to raise capital via its ATM agreement and Lincoln Park equity line. Subsequent to quarter-end, the company raised an additional ~$1.6 million through these facilities.
- Risks: Key risks include the need for additional capital to fund operations and commercialization, the uncertainty of FDA approval for product candidates, and the potential dilution of shareholders from future equity issuances. The promissory note contains restrictive covenants and potential penalty triggers upon default.
Investor Verification Checklist
- Cash Runway: Verify if the $9.5 million cash balance is sufficient to reach the mid-2025 NDA submission and subsequent commercialization phases without further dilution.
- Debt Covenants: Review the specific "Major" and "Minor" Trigger Events in the Streeterville Capital promissory note that could accelerate debt repayment or increase the principal balance.
- Grant Terms: Confirm the milestones required to receive the remaining $2 million of the $3 million grant for CTx-2103 and the royalty obligations ($500k/quarter) upon commercialization.
- Commercialization Plan: Assess the status of the Master Services Agreement with Indegene, Inc., which replaced the previous joint commercialization agreement, and the terms for outsourcing sales and marketing.
- Regulatory Timeline: Monitor the outcome of the April 2025 Pre-NDA meeting and the actual filing date of the NDA for CTx-1301.